DGAP-News

RedHill Biopharma Ltd.: RedHill Biopharma Announces Phase Ib/II Study with YELIVA(TM) Initiated for Multiple Myeloma at a Leading U.S. Academic Medical Center

DGAP-News: RedHill Biopharma Ltd. / Key word(s): Study
RedHill Biopharma Ltd.: RedHill Biopharma Announces Phase Ib/II Study with
YELIVA(TM) Initiated for Multiple Myeloma at a Leading U.S. Academic Medical
Center

13.09.2016 / 09:30
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

RedHill Biopharma Announces Phase Ib/II Study with YELIVA(TM) Initiated for
Multiple Myeloma at a Leading U.S. Academic Medical Center

- The Phase Ib/II clinical study is intended to evaluate the safety and
efficacy of YELIVA(TM) (ABC294640) in patients with refractory or
relapsed multiple myeloma and is supported by a $2 million grant from
the National Cancer Institute (NCI), awarded to Apogee Biotechnology
Corp., with additional support from RedHill

- YELIVA(TM) is a proprietary, first-in-class, orally-administered
sphingosine kinase-2 (SK2) selective inhibitor, with anti-cancer and
anti-inflammatory activities

- RedHill is pursuing several clinical studies with YELIVA(TM), targeting
multiple inflammatory and oncology indications, including a Phase II
study for the treatment of advanced hepatocellular carcinoma to be
initiated in the coming weeks at the Medical University of South
Carolina (MUSC) and additional clinical centers, supported by an NCI
grant awarded to MUSC with additional support from RedHill

- Final positive results from the Phase I study with YELIVA(TM) in
patients with advanced solid tumors confirmed that the study
successfully met its primary and secondary endpoints, demonstrating
that the drug is well-tolerated and can be safely administered to
cancer patients at doses that provide circulating drug levels that are
predicted to have therapeutic activity

- Worldwide sales of multiple myeloma therapies are estimated to exceed
$12 billion in 2016


TEL-AVIV, Israel, September 13, 2016 RedHill Biopharma Ltd. (NASDAQ: RDHL)
(TASE: RDHL) ("RedHill" or the "Company"), a biopharmaceutical company
primarily focused on development and commercialization of late clinical-
stage, proprietary, orally-administered, small molecule drugs for
gastrointestinal and inflammatory diseases and cancer, announced that a
Phase Ib/II clinical study evaluating YELIVA(TM) (ABC294640) in patients
with refractory or relapsed multiple myeloma has been initiated.

The open-label, dose escalation Phase Ib/II study is being conducted at
Duke University Medical Center and will enroll up to 77 patients with
refractory or relapsed multiple myeloma who have previously been treated
with proteasome inhibitors and immunomodulatory drugs.